Morgan Stanley Initiates Coverage On Inovalon Holdings On Balanced Risk/Reward

In a report published Monday, Morgan Stanley analyst Ricky R. Goldwasser initiated coverage on

with an Equal-Weight rating and $33.00 price target. In the report, Morgan Stanley noted, "As a leader in the healthcare analytics cloud, INOV is benefitting from the evolution of the US healthcare system while offering company-specific outperformance as it expands its TAM. We are bullish on INOV's positioning, but w/ 8% upside to our $33 PT and a balanced risk reward, rate shares E-W." Inovalon Holdings closed on Friday at $30.53.